**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Drug Abuse**

**Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel, NIDA R13 Conference Grant Review.

**Date:** November 1, 2011.

**Time:** 8 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

**Contact Person:** Minna Liang, PhD, Scientific Review Officer, Grants Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, 6001 Executive Blvd., Room 4226, MSC 9550, Bethesda, MD 20892–9550, 301–435–1432, liangm@nida.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing necessary to complete the review process.

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Drug Abuse**

**Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel, NIDA R13 Conference Grant Review.

**Date:** November 4, 2011.

**Time:** 8 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Embassy Suites Hotel, 4300 Military Road, Washington, DC 20015.

**Contact Person:** Dennis E. Leszczynski, PhD, Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health And Human Development, NIH, 6100 Executive Blvd., Room S601, Rockville, MD 20852, 301–435–2717, leszczyd@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

**Dated:** October 17, 2011.

**Jennifer S. Spaeth,**

Director, Office of Federal Advisory Committee Policy.

**FR Doc.** 2011–27203 Filed 10–20–11; 8:45 am

**BILLING CODE 4140–01–P**
limitations imposed by the review and funding cycle.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel, Research Education Program for Clinical Researchers and Clinicians.

**Date:** November 1, 2011.

**Time:** 11 a.m. to 2 p.m.

**Agenda** To review and evaluate grant applications.

**Place:** National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

**Contact Person:** Gerald L. McLaughlin, PhD, Chief, Grants Review Branch and Contracts Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892–9550, 301–402–6626, gm145a@nih.gov.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel, DIDARP Review.

**Date:** December 13, 2011.

**Time:** 9 a.m. to 5 p.m.

**Agenda** To review and evaluate grant applications.

**Place:** Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.

**Contact Person:** Nadine Rogers, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4229, MSC 9550, Bethesda, MD 20892–9550, 301–402–2105, rogersn2@nida.nih.gov.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel, B/START Review Committee.

**Date:** November 4, 2011.

**Time:** 8 a.m. to 8 p.m.

**Agenda** To review and evaluate grant applications.

**Place:** National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

**Contact Person:** Mark Swieter, PhD, Chief, Extramural Activities Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4235, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892–9550, 301–435–1389, ms80x@nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel, HIV/AIDS Implementation Science Targeting Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892–9550, 301–402–6626, gm145a@nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel, PEPFAR (R01).

**Date:** November 15, 2011.

**Time:** 9 a.m. to 5:30 p.m.

**Agenda** To review and evaluate grant applications.

**Place:** Hilton Garden Inn—Bethesda, 7301 Waverly Street, Bethesda, MD 20814.

**Contact Person:** Nadine Rogers, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4229, MSC 9550, Bethesda, MD 20892–9550, 301–402–2105, rogersn2@nida.nih.gov.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel, HIV/AIDS Implementation Science Targeting Drug Using Populations: PEPFAR (R01).

**Date:** November 17, 2011.

**Time:** 9 a.m. to 5 p.m.

**Agenda** To review and evaluate grant applications.

**Place:** National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

**Contact Person:** Gerald L. McLaughlin, PhD, Chief, Grants Review Branch and Contracts Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892–9550, 301–402–6626, gm145a@nih.gov.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel, DIDARP Review.

**Date:** December 13, 2011.

**Time:** 9 a.m. to 5 p.m.

**Agenda** To review and evaluate grant applications.

**Place:** Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.

**Contact Person:** Nadine Rogers, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4229, MSC 9550, Bethesda, MD 20892–9550, 301–402–2105, rogersn2@nida.nih.gov.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel, Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS.

**Dated:** October 17, 2011.

**Jennifer S. Spaeth,**

Director, Office of Federal Advisory Committee Policy.

**[FR Doc. 2011–27294 Filed 10–20–11; 8:45 am]**

**BILLING CODE 4140–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Prospective Grant of Exclusive License: The Development of a Companion Diagnostic Kit for Predicting Therapeutic Efficacy of Anti-Cancer Agents**

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in US Patent Application 61/144,501 entitled “Ratio Based Biomarker of Survival Utilizing PTEN and Phospho-AKT” [HHS Ref. E–025–2009/0–US–01], and all continuing applications and foreign counterparts, to 20/20 GeneSystems, Inc. The patent rights in this invention have been assigned to the Government of the United States of America.

The prospective exclusive license territory may be worldwide, and the field of use may be limited to:

- the use of the Licensed Patents Rights limited to an FDA-approved (i) Laboratory Developed Test (LDT) offered as a service or (ii) in vitro diagnostic (IVD) kit distributed in commerce for human use of a protein panel predictive of the therapeutic effect of an anti-cancer agent in the treatment of kidney, lung, and breast cancers that includes at least one of the following proteins (phosphorylated or unphosphorylated): PTEN, Akt, mTOR.

**DATES:** Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 21, 2011 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Patrick P. McCue, Ph.D., Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–5560; Facsimile: (301) 402–0220; E-mail: mccuepat@mail.nih.gov.

**SUPPLEMENTARY INFORMATION:** This invention concerns methods for the diagnosis of cancer. The use of the prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective exclusive license may be granted unless the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7 within thirty (30) days from the date of this published notice.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.